Literature DB >> 21569052

Plasma concentrations of chloramphenicol after subcutaneous administration to koalas (Phascolarctos cinereus) with chlamydiosis.

M Govendir1, J Hanger, J J Loader, B Kimble, J E Griffith, L A Black, M B Krockenberger, D P Higgins.   

Abstract

Nine mature koalas with chlamydiosis, typically keratoconjunctivitis and/or urogenital tract infection, were treated with daily subcutaneous injections of chloramphenicol at 60 mg/kg for 45 days (five koalas), or for a shorter duration (four koalas). All koalas were initially positive for Chlamydia pecorum as determined by real-time polymerase chain reaction (qPCR). Plasma chloramphenicol concentrations were determined at t = 0, 1, 2, 4, 8, and 24 h after the day 1 injection (nine koalas) and after the day 15 injection (seven koalas). Chloramphenicol reached a median (and range) maximum plasma concentration of 3.03 (1.32-5.03 μg/mL) at 4 (1-8 h) after the day 1 injection and 4.82 (1.97-27.55 μg/mL) at 1 (1-2 h) after day 15. The median (and range) of AUC(0-24) on day 1 and day 15 were 48.14 (22.37-81.14 μg·h/mL) and 50.83 (28.43-123.99 μg·h/mL), respectively. The area under the moment curve (AUMC)(0-24) median (and range) for day 1 and day 15 were 530.03 (233.05-798.97 h) and 458.15 (291.72-1093.58 h), respectively. Swabs were positive for chlamydial DNA pretreatment, and all koalas except one, produced swabs negative for chlamydial DNA during treatment and which remained so, for 2-63 days after treatment, however whether chloramphenicol treatment prevented long-term recrudescence of infection was not established. At this dose and dosing frequency, chloramphenicol appeared to control mild chlamydial infection and prevent shedding, but severe urogenital disease did not appear to respond to chloramphenicol at this dosage regime. For koalas affected by severe chlamydiosis, antibiotics alone are not sufficient to effect a cure, possibly because of structural or metabolic changes associated with chronic disease and inflammation.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21569052     DOI: 10.1111/j.1365-2885.2011.01307.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  10 in total

1.  Identification of MHCII variants associated with chlamydial disease in the koala (Phascolarctos cinereus).

Authors:  Quintin Lau; Joanna E Griffith; Damien P Higgins
Journal:  PeerJ       Date:  2014-06-19       Impact factor: 2.984

2.  A Prototype Recombinant-Protein Based Chlamydia pecorum Vaccine Results in Reduced Chlamydial Burden and Less Clinical Disease in Free-Ranging Koalas (Phascolarctos cinereus).

Authors:  Courtney Waugh; Shahneaz Ali Khan; Scott Carver; Jonathan Hanger; Joanne Loader; Adam Polkinghorne; Kenneth Beagley; Peter Timms
Journal:  PLoS One       Date:  2016-01-12       Impact factor: 3.240

3.  Chlamydia Serine Protease Inhibitor, targeting HtrA, as a New Treatment for Koala Chlamydia infection.

Authors:  Amba Lawrence; Tamieka Fraser; Amber Gillett; Joel D A Tyndall; Peter Timms; Adam Polkinghorne; Wilhelmina M Huston
Journal:  Sci Rep       Date:  2016-08-17       Impact factor: 4.379

4.  Characterization of shifts of koala (Phascolarctos cinereus) intestinal microbial communities associated with antibiotic treatment.

Authors:  Katherine E Dahlhausen; Ladan Doroud; Alana J Firl; Adam Polkinghorne; Jonathan A Eisen
Journal:  PeerJ       Date:  2018-03-12       Impact factor: 2.984

5.  Vaccination of koalas (Phascolarctos cinereus) against Chlamydia pecorum using synthetic peptides derived from the major outer membrane protein.

Authors:  Sharon Nyari; Shahneaz Ali Khan; Galit Rawlinson; Courtney A Waugh; Andrew Potter; Volker Gerdts; Peter Timms
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

6.  Physiological stress levels in wild koala sub-populations facing anthropogenic induced environmental trauma and disease.

Authors:  Edward Narayan
Journal:  Sci Rep       Date:  2019-04-15       Impact factor: 4.379

7.  Optimising the short and long-term clinical outcomes for koalas (Phascolarctos cinereus) during treatment for chlamydial infection and disease.

Authors:  Amy Robbins; Joanne Loader; Peter Timms; Jonathan Hanger
Journal:  PLoS One       Date:  2018-12-27       Impact factor: 3.240

8.  Therapeutic effect of a Chlamydia pecorum recombinant major outer membrane protein vaccine on ocular disease in koalas (Phascolarctos cinereus).

Authors:  Sharon Nyari; Rosemary Booth; Bonnie L Quigley; Courtney A Waugh; Peter Timms
Journal:  PLoS One       Date:  2019-01-07       Impact factor: 3.240

9.  Koala cathelicidin PhciCath5 has antimicrobial activity, including against Chlamydia pecorum.

Authors:  Emma Peel; Yuanyuan Cheng; Julianne T Djordjevic; Denis O'Meally; Mark Thomas; Michael Kuhn; Tania C Sorrell; Wilhelmina M Huston; Katherine Belov
Journal:  PLoS One       Date:  2021-04-14       Impact factor: 3.240

10.  Pharmacokinetic Profile of Doxycycline in Koala Plasma after Weekly Subcutaneous Injections for the Treatment of Chlamydiosis.

Authors:  Chien-Jung Chen; Amber Gillett; Rosemary Booth; Benjamin Kimble; Merran Govendir
Journal:  Animals (Basel)       Date:  2022-01-20       Impact factor: 2.752

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.